The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Open accessAbstract
N-terminal natriuretic peptide type B (NT-proBNP) is a marker of cardiac dysfunction in light chain amyloidosis (AL) and a powerful prognostic determinant. Serum NT-proBNP and circulating free light chains (FLCs) were measured at enrollment and after 3 cycles of chemotherapy in 51 patients with cardiac AL. In patients (n = 22, 43%) in whom FLCs decreased by more than 50% (hematologic response), NT-proBNP concentration decreased by a median of 48%, whereas in the remaining patients it increased by 47% (P = .01). The reduction of NT-proBNP was greater in patients (n = 9) in whom amyloidogenic FLCs disappeared at immunofixation (median 53%), than in the remaining responding patients (median 31%, P = .04). Left ventricular wall thickness decreased by at least 2 mm in 3 of 20 patients in whom NT-proBNP improved. Fifteen patients died. Thirteen of them, in whom NT-proBNP and FLCs did not improve, died after a median of 1.8 months. The decrease of FLCs translates into a simultaneous decrease of NT-proBNP and improved survival. Patients in whom chemotherapy fails to induce such a decrease are at risk of early death. Cardiac function in AL can rapidly improve due to a reduction of the circulating amyloidogenic precursor, despite the amount of cardiac amyloid deposits remaining apparently unaltered, as measured by echocardiography.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Molecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
Self-citationGertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Self-citationPrimary systemic amyloidosis: clinical and laboratory features in 474 cases.
Kyle, R. A., & Ma, G. (1995) · PubMed · Cited by 1,255
Dispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.029 · Cited by 985
Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine
Bradwell, A. R., Carr-Smith, H. D., Mead, G. P., Tang, L. X., Showell, P. J., Drayson, M. T., & Drew, R. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.673 · Cited by 650
Self-citationKatzmann, J. A., Clark, R. J., Abraham, R. S., Bryant, S. C., Lymp, J. F., Bradwell, A. R., & Kyle, R. A. (2002) · PubMed · Cited by 620
Self-citationKatzmann, J. A., Clark, R. J., Abraham, R. S., Bryant, S., Lymp, J. F., Bradwell, A. R., & Kyle, R. A. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.9.1437 · Cited by 620
Self-citationSkinner, M., Sanchorawala, V., Seldin, D. C., Dember, L. M., Falk, R. H., Berk, J. L., Anderson, J. J., O'Hara, C., Finn, K. T., Libbey, C. A., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-2-200401200-00008 · Cited by 618
Lachmann, H. J., Gallimore, R., Gillmore, J. D., Carr‐Smith, H. D., Bradwell, A. R., Pepys, M. B., & Hawkins, P. N. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04433.x · Cited by 435
Self-citation
Cited by
Palladini, G., Dispenzieri, A., Gertz, M. A., Kumar, S., Wechalekar, A., Hawkins, P. N., Schönland, S., Hegenbart, U., Comenzo, R., Kastritis, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7614 · Cited by 974
Self-citationDispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia · doi:10.1038/leu.2008.307 · Cited by 815
Self-citationAmyloidosis: Pathogenesis and New Therapeutic Options
Merlini, G., Seldin, D. C., & Gertz, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2271 · Cited by 509
Self-citationMerlini, G., & Stone, M. J. (2006) · Blood · doi:10.1182/blood-2006-03-001164 · Cited by 463
Self-citationTargeting protein aggregation for the treatment of degenerative diseases
Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4593 · Cited by 419
Metadata
- Authors
- Palladini, G., Lavatelli, F., Russo, P., Perlini, S., Perfetti, V., Bosoni, T., Obici, L., Bradwell, A. R., D'Eril, G. M., Fogari, R., Moratti, R., & Merlini, G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-05-15
- Volume
- 107
- Issue
- 10
- Pages
- 3854-3858
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2128583637
- Cited by
- 311
- References
- 15
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. https://app.cochat.ai/papers/10.1182/blood-2005-11-4385
- The paper
- Palladini, G., Lavatelli, F., Russo, P., Perlini, S., Perfetti, V., Bosoni, T., Obici, L., Bradwell, A. R., D'Eril, G. M., Fogari, R., Moratti, R., & Merlini, G. (2006). Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. https://doi.org/10.1182/blood-2005-11-4385
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.